CBER to propose rule on reporting biologics manufacturing errors and accidents.
Executive Summary
FDA BIOLOGICS MANUFACTURING ERROR/ACCIDENT REPORTING REQUIREMENTS will be outlined in a proposed rule for comment due out of the agency in the next two to three months. Addressing a PDA/FDA meeting in Bethesda, Md. Oct. 1, CBER Division of Inspection and Surveillance Reporting of Errors and Accidents Director Boyd Fogle advised manufacturers of traditional biologic products, in vitro diagnostics, vaccines and plasma derivatives to "be aware of this proposal." The proposed regulation, 21 CFR 600.14, has received significant attention by blood products manufacturers but has been largely overlooked by traditional biologics manufacturers.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth